MedTrace Logo

Study of KW-6002 (Istradefylline) in Parkinson's Disease in Patients With Motor Response Complications on Levodopa

NCT00203957 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2013-06-11

No results posted yet for this study

Summary

The purpose of this study is to confirm the long term tolerability and safety of oral 20 or 40 mg/d doses of Istradefylline.

Conditions

Interventions

DRUG

Istradefylline

Patients will receive starting dose of 40mg/d. The allowable doses are 20 and 40mg/d

DRUG

Istradefylline

Patients will receive starting dose of 40mg/d. The allowable doses are 20 and 40mg/d

Sponsors & Collaborators

  • University of Chicago

    lead OTHER

Principal Investigators

  • Arif Dalvi, M.D. · University of Chicago

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-03-31
Primary Completion
2007-02-28
Completion
2007-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00203957 on ClinicalTrials.gov